Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin-based TACE regimens for unresectable hepatocellular carcinoma
ChiCTR-TRC-09000345Phase 4Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oxaliplatin, gemcitabine and floxuridine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: overall survival and time to progression. Started Dec 2005; status: completed.
02
Drugs
oxaliplatingemcitabinefloxuridine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-09000345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000345.